MX388845B - Uso de pridopidina para tratar el sindrome de rett. - Google Patents
Uso de pridopidina para tratar el sindrome de rett.Info
- Publication number
- MX388845B MX388845B MX2019003069A MX2019003069A MX388845B MX 388845 B MX388845 B MX 388845B MX 2019003069 A MX2019003069 A MX 2019003069A MX 2019003069 A MX2019003069 A MX 2019003069A MX 388845 B MX388845 B MX 388845B
- Authority
- MX
- Mexico
- Prior art keywords
- pridopidine
- rett syndrome
- treat
- subject
- treat rett
- Prior art date
Links
- 208000006289 Rett Syndrome Diseases 0.000 title abstract 2
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title abstract 2
- 229950003764 pridopidine Drugs 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395854P | 2016-09-16 | 2016-09-16 | |
| PCT/US2017/051803 WO2018053280A1 (en) | 2016-09-16 | 2017-09-15 | Use of pridopidine for treating rett syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019003069A MX2019003069A (es) | 2019-09-02 |
| MX388845B true MX388845B (es) | 2025-03-20 |
Family
ID=61619744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003069A MX388845B (es) | 2016-09-16 | 2017-09-15 | Uso de pridopidina para tratar el sindrome de rett. |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP3512506B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6977029B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109982686A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017326013B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019005040A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3036984C (cg-RX-API-DMAC7.html) |
| DK (2) | DK4005570T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2909557T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE058314T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL265342B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX388845B (cg-RX-API-DMAC7.html) |
| PL (2) | PL3512506T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018053280A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA122999C2 (uk) | 2013-06-21 | 2021-02-03 | Прайлінія Н'Юротерапьютікс Лтд. | Застосування придопідину для лікування хвороби гантінгтона |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| EP3503890B1 (en) | 2016-08-24 | 2024-12-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating dystonias |
| MX390627B (es) | 2016-08-24 | 2025-03-21 | Prilenia Neurotherapeutics Ltd | Uso de pridopidina para el tratamiento de la disminucion funcional. |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| CN109982686A (zh) | 2016-09-16 | 2019-07-05 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗rett综合征的用途 |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| BR112021015346A2 (pt) | 2019-02-04 | 2021-10-05 | Prilenia Neurotherapeutics Ltd. | Uso de pridopidina de baixa dose para a doença de parkinson e outras doenças associadas ao parkinsonismo |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| JP2013536825A (ja) | 2010-09-03 | 2013-09-26 | イバックス・インターナショナル・ゲーエムベーハー | ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体 |
| WO2013086425A1 (en) * | 2011-12-08 | 2013-06-13 | IVAX International GmbH | The hydrobromide salt of pridopidine |
| US20130267552A1 (en) | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
| UA122999C2 (uk) | 2013-06-21 | 2021-02-03 | Прайлінія Н'Юротерапьютікс Лтд. | Застосування придопідину для лікування хвороби гантінгтона |
| JP6949487B2 (ja) * | 2014-01-22 | 2021-10-13 | プリレニア・ニューロセラピューティクス・エルティーディーＰｒｉｌｅｎｉａ Ｎｅｕｒｏｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ | プリドピジンの調節放出製剤 |
| EP4282479A3 (en) * | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| WO2016138135A1 (en) * | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| CN109982686A (zh) | 2016-09-16 | 2019-07-05 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗rett综合征的用途 |
-
2017
- 2017-09-15 CN CN201780071045.XA patent/CN109982686A/zh active Pending
- 2017-09-15 DK DK22150695.9T patent/DK4005570T3/da active
- 2017-09-15 CA CA3036984A patent/CA3036984C/en active Active
- 2017-09-15 DK DK17851614.2T patent/DK3512506T3/da active
- 2017-09-15 AU AU2017326013A patent/AU2017326013B2/en active Active
- 2017-09-15 ES ES17851614T patent/ES2909557T3/es active Active
- 2017-09-15 JP JP2019514217A patent/JP6977029B2/ja active Active
- 2017-09-15 HU HUE17851614A patent/HUE058314T2/hu unknown
- 2017-09-15 EP EP17851614.2A patent/EP3512506B1/en active Active
- 2017-09-15 MX MX2019003069A patent/MX388845B/es unknown
- 2017-09-15 WO PCT/US2017/051803 patent/WO2018053280A1/en not_active Ceased
- 2017-09-15 BR BR112019005040A patent/BR112019005040A2/pt not_active Application Discontinuation
- 2017-09-15 PL PL17851614T patent/PL3512506T3/pl unknown
- 2017-09-15 PL PL22150695.9T patent/PL4005570T3/pl unknown
- 2017-09-15 ES ES22150695T patent/ES2986807T3/es active Active
- 2017-09-15 EP EP22150695.9A patent/EP4005570B1/en active Active
-
2019
- 2019-03-13 IL IL265342A patent/IL265342B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109982686A (zh) | 2019-07-05 |
| JP2019532926A (ja) | 2019-11-14 |
| ES2909557T3 (es) | 2022-05-09 |
| ES2986807T3 (es) | 2024-11-12 |
| PL4005570T3 (pl) | 2024-09-23 |
| IL265342A (en) | 2019-05-30 |
| AU2017326013B2 (en) | 2020-12-24 |
| DK3512506T3 (da) | 2022-04-19 |
| DK4005570T3 (da) | 2024-08-19 |
| AU2017326013A1 (en) | 2019-04-11 |
| EP3512506A1 (en) | 2019-07-24 |
| EP4005570A1 (en) | 2022-06-01 |
| MX2019003069A (es) | 2019-09-02 |
| CA3036984C (en) | 2023-07-18 |
| HUE058314T2 (hu) | 2022-07-28 |
| PL3512506T3 (pl) | 2022-05-30 |
| JP6977029B2 (ja) | 2021-12-08 |
| IL265342B2 (en) | 2023-06-01 |
| WO2018053280A1 (en) | 2018-03-22 |
| CA3036984A1 (en) | 2018-03-22 |
| EP3512506A4 (en) | 2020-05-27 |
| EP4005570B1 (en) | 2024-05-15 |
| EP3512506B1 (en) | 2022-01-26 |
| BR112019005040A2 (pt) | 2019-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX388845B (es) | Uso de pridopidina para tratar el sindrome de rett. | |
| BR112018010464A2 (pt) | formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas | |
| CL2017000285A1 (es) | Terapia combinada para el tratamiento de un paramixovirus | |
| ECSP17018120A (es) | Triazolopirazinonas como inhibidores de pde1 | |
| MX2019002190A (es) | Uso de pridopidina para tratar distonías. | |
| DOP2017000254A (es) | Imidazopirazinonas como inhibidores de pde1 | |
| CL2016000326A1 (es) | Composiciones y método para tratar condiciones asociadas con el complemento | |
| EA201792496A1 (ru) | Способы лечения воспаления или нейропатической боли | |
| CL2019001381A1 (es) | Método para el tratamiento de glomeruloesclerosis segmentaria focal. | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| MX377534B (es) | Compuestos para usarse en el tratamiento de hiperinsulinemia. | |
| BR112018000776A2 (pt) | métodos para tratamento de câncer usando apilimod | |
| MX374385B (es) | Apilimod para uso en el tratamiento de melanoma. | |
| BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. | |
| UY36286A (es) | Tratamientos médicos basados en anamorelina | |
| MX383323B (es) | Grelina para uso en el tratamiento de lesión del cerebro traumática leve. | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| CY1122403T1 (el) | Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης | |
| MX2019006694A (es) | Oxabicicloheptanos para la modulacion de la respuesta inmunitaria. | |
| ECSP16061208A (es) | Quinazolin-thf-aminas como inhibidores de pde1 | |
| BR112017011685A2 (pt) | composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas | |
| MX2016009597A (es) | Terapias para el influenzavirus a subtipo h7n9. | |
| DOP2016000263A (es) | Quinazolin-thf-aminas halogenadas como inhibidores de pde1 | |
| CL2016001192A1 (es) | Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas. |